ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of small molecule drugs aimed at addressing unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA is also advancing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive therapy for schizophrenia, both of which are currently in Phase III clinical trials. Additionally, the company is exploring the use of pimavanserin for major depressive disorder. ACADIA maintains subsidiaries in Sweden and Denmark and is focused on expanding its portfolio of drug candidates, seeking to discover innovative therapies for various neurological and psychiatric conditions.
Top Stages
1 past transactions
CerSci Therapeutics
Acquisition in 2020
CerSci Therapeutics Inc. is a Dallas, Texas-based biotechnology company focused on developing non-opioid alternatives for the treatment of acute post-operative and chronic neuropathic pain, including pain associated with diabetes and chemotherapy. Founded in 2015, the company is advancing its lead drug candidate, CT-044, which has received approval from the United States Food and Drug Administration to proceed with Phase I clinical trials. CT-044 is a small molecule designed to decompose radical species such as peroxynitrite and hydrogen peroxide, and it is intended to address both acute and chronic pain conditions. As of August 2020, CerSci Therapeutics operates as a subsidiary of ACADIA Pharmaceuticals Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.